Caris Life Sciences’ IPO raised $494 million to expand its comprehensive molecular profiling and AI-driven cancer diagnostics, leveraging data from over 6.5 million tests. Its assays support therapy selection and biopharma collaborations. Furthermore, Adaptive Biotechnologies gained positive market coverage for its ClonoSeq MRD test in hematologic cancers. Additional advancements include automated fruit grading powered by machine vision and deep learning, as well as rapid epigenetic-based methylation biomarkers for liver transplant rejection, enhancing early clinical intervention capabilities.